A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-γ
<p>Abstract</p> <p>Background</p> <p>Chronic granulomatous disease (CGD) is a rare disorder of phagocytes in which absence of superoxide and hydrogen peroxide production in phagocytes predisposes patients to bacterial and fungal infections. The most common fungal infect...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2005-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_9f65c4c7c7ca40b0bac996b2a2aa8bc2 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Gerami-Shoar Mohsen |e author |
| 700 | 1 | 0 | |a Saadat Farshid |e author |
| 700 | 1 | 0 | |a Zomorodian Kamiar |e author |
| 700 | 1 | 0 | |a Mamishi Setareh |e author |
| 700 | 1 | 0 | |a Tarazooie Bita |e author |
| 700 | 1 | 0 | |a Siadati Seyad Ahmad |e author |
| 245 | 0 | 0 | |a A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-γ |
| 260 | |b BMC, |c 2005-03-01T00:00:00Z. | ||
| 500 | |a 10.1186/1476-0711-4-4 | ||
| 500 | |a 1476-0711 | ||
| 520 | |a <p>Abstract</p> <p>Background</p> <p>Chronic granulomatous disease (CGD) is a rare disorder of phagocytes in which absence of superoxide and hydrogen peroxide production in phagocytes predisposes patients to bacterial and fungal infections. The most common fungal infections in these patients are caused by <it>Aspergillus </it>species.</p> <p>Case presentation</p> <p>Here, we describe <it>Aspergillus </it>osteomyelitis of the ribs and hepatic abscess in a 5-year-old boy. The patient was successfully treated with Amphotericin B and INF-γ.</p> <p>Conclusion</p> <p>With respect to the high frequency of aspergillosis in the CGD patient, immune deficiency should be investigated in patients with invasive aspergillosis. Moreover, using antifungal drugs as prophylaxis can improve the quality of life in these patients.</p> | ||
| 546 | |a EN | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Infectious and parasitic diseases | ||
| 690 | |a RC109-216 | ||
| 690 | |a Microbiology | ||
| 690 | |a QR1-502 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Annals of Clinical Microbiology and Antimicrobials, Vol 4, Iss 1, p 4 (2005) | |
| 787 | 0 | |n http://www.ann-clinmicrob.com/content/4/1/4 | |
| 787 | 0 | |n https://doaj.org/toc/1476-0711 | |
| 856 | 4 | 1 | |u https://doaj.org/article/9f65c4c7c7ca40b0bac996b2a2aa8bc2 |z Connect to this object online. |